tiprankstipranks
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
US Market
Holding TRDA?
Track your performance easily

Entrada Therapeutics Inc (TRDA) Ownership - Who Owns Entrada Therapeutics Inc?

83 Followers

Entrada Therapeutics Inc (TRDA) Ownership Overview

17.17%14.61%42.34%7.27%18.61%
17.17% Insiders
42.34% Other Institutional Investors
7.27% ETFs
18.61% Public Companies and
Individual Investors
The ownership structure of Entrada Therapeutics Inc (TRDA) stock is a mix of institutional, retail, and individual investors. Approximately 64.22% of the company’s stock is owned by Institutional Investors, 17.17% is owned by Insiders, and 18.61% is owned by Public Companies and Individual Investors.
The ownership structure of Entrada Therapeutics Inc (TRDA) stock is a mix of institutional, retail, and individual investors. Approximately 56.96% of the company’s stock is owned by Institutional Investors, 17.17% is owned by Insiders, and 7.27% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
May 16, 2024
Peter Kim
Director
xxxxxxxxxxxxx
$364500
May 10, 2024
Peter Kim
Director
xxxxxxxxxxxxx
$63283
Apr 10, 2024
Peter Kim
Director
xxxxxxxxxxxxx
$35282
Apr 01, 2024
Peter Kim
Director
xxxxxxxxxxxxx
$20790

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$206429
Sep 30, 2024
xxxxxxxxxxxxx
$916149

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
4,865,819Institution13.00%96,781,140
4,501,658Insider12.03%89,537,978
1,942,377Institution5.19%38,633,879
1,166,756Institution3.12%23,206,777
1,132,357Insider3.03%22,522,581
1,028,780Institution2.75%20,462,434
970,062Institution2.59%19,294,533
581,298Institution1.55%11,562,017
569,869Institution1.52%11,334,694
325,753Insider0.87%6,479,227

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,942,377Institution5.19%38,633,879
970,062Institution2.59%19,294,533
581,298Institution1.55%11,562,017
569,869Institution1.52%11,334,694
287,416Institution0.77%5,716,704
276,252Institution0.74%5,494,652
195,225Institution0.52%3,883,025
122,416Institution0.33%2,434,854
118,764Institution0.32%2,362,216
67,870Institution0.18%1,349,934

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
683,176Institution1.83%13,588,371
686,724Institution1.84%11,770,449
292,648Institution0.78%5,015,987
243,082Institution0.65%4,834,901
111,063Institution0.30%2,202,379
112,861Institution0.30%1,934,438
74,073Institution0.20%1,473,312
57,077Institution0.15%1,135,262
55,498Institution0.15%951,236
47,017Institution0.13%932,347

FAQ

Who Owns Entrada Therapeutics Inc (TRDA)?
According to the latest TipRanks data, approximately 42.34% of the company's stock is held by institutional investors, 17.17% is held by insiders, and 18.61% is held by retail investors.
    What percentage of Entrada Therapeutics Inc (TRDA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 42.34% of Entrada Therapeutics Inc (TRDA) stock is held by institutional investors.
      What percentage of Entrada Therapeutics Inc (TRDA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 18.61% of Entrada Therapeutics Inc (TRDA) stock is held by retail investors.
        Who owns the most shares of Entrada Therapeutics Inc (TRDA)?
        Felix Baker owns the most shares of Entrada Therapeutics Inc (TRDA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis